Edgardo S Santos

Summary

Affiliation: University of Miami
Country: USA

Publications

  1. doi request reprint Targeting important pathways in head and neck cancer: from the bench to the clinic
    Edgardo S Santos
    University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA
    Expert Rev Anticancer Ther 8:1819-35. 2008
  2. pmc Emerging role of multikinase inhibitors for refractory thyroid cancer
    Cesar A Perez
    University of Miami Miller School of Medicine Sylvester Comprehensive Cancer Center, Miami, USA
    Biologics 6:257-65. 2012
  3. pmc Safety and efficacy of pemetrexed in maintenance therapy of non-small cell lung cancer
    Michel Velez
    Division of Hematology Oncology, Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine, Miami, FL, USA
    Clin Med Insights Oncol 6:117-24. 2012
  4. pmc The role of proteasome inhibition in nonsmall cell lung cancer
    Mauricio Escobar
    Leonard M Miller School of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA
    J Biomed Biotechnol 2011:806506. 2011
  5. doi request reprint Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor
    Edgardo S Santos
    Section of Thoracic Oncology, Sylvester Comprehensive Cancer Center, University of Miami Leonard M Miller School of Medicine, 1475 NW 12th Ave, D8 4, Miami, FL 33136, USA
    Invest New Drugs 30:1261-9. 2012
  6. doi request reprint How is gene-expression profiling going to challenge the future management of lung cancer?
    Edgardo S Santos
    Hematology Oncology Fellowship Program, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, 1475 NW 12th Avenue, Miami, FL 33136, USA
    Future Oncol 5:827-35. 2009
  7. doi request reprint Gene expression profiling and non-small-cell lung cancer: where are we now?
    Edgardo S Santos
    University of Miami Leonard M Miller School of Medicine Sylvester Comprehensive Cancer Center, FL, USA
    Clin Lung Cancer 10:168-73. 2009
  8. doi request reprint Controversies in the management of stage IIIA non-small-cell lung cancer
    Edgardo S Santos
    Hematology Oncology Fellowship Program University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, 1475 NW 12th Avenue, Suite 3510, Miami, FL 33136, USA
    Expert Rev Anticancer Ther 8:1913-29. 2008
  9. ncbi request reprint New targets for non-small-cell lung cancer therapy
    Manrique Alvarez
    University of Miami Miller s School Of Medicine, The William Harrington Latin American Training Program WHLTP, Division of Hematology Medical Oncology, Sylvester Comprehensive Cancer Center, 1475 NW 12 Avenue, Miami, FL 33136, USA
    Expert Rev Anticancer Ther 7:1423-37. 2007
  10. doi request reprint Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC
    Michel Velez
    Department of Medicine, University of Miami Miller School of Medicine at FAU, Atlantis, FL, USA
    Expert Rev Anticancer Ther 10:549-57. 2010

Collaborators

Detail Information

Publications26

  1. doi request reprint Targeting important pathways in head and neck cancer: from the bench to the clinic
    Edgardo S Santos
    University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA
    Expert Rev Anticancer Ther 8:1819-35. 2008
    ..In this review, we discuss other cellular pathways that have shown to be involved in the carcinogenesis of squamous cell carcinoma of the head and neck and the actual efforts to target these mechanisms...
  2. pmc Emerging role of multikinase inhibitors for refractory thyroid cancer
    Cesar A Perez
    University of Miami Miller School of Medicine Sylvester Comprehensive Cancer Center, Miami, USA
    Biologics 6:257-65. 2012
    ..The molecular rationale for the use of these drugs for thyroid cancer is discussed as well as their promising clinical results...
  3. pmc Safety and efficacy of pemetrexed in maintenance therapy of non-small cell lung cancer
    Michel Velez
    Division of Hematology Oncology, Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine, Miami, FL, USA
    Clin Med Insights Oncol 6:117-24. 2012
    ..More research work needs to be done to identify which patients truly benefit from these approaches, and to whom we should offer maintenance or switch maintenance vs. close observation...
  4. pmc The role of proteasome inhibition in nonsmall cell lung cancer
    Mauricio Escobar
    Leonard M Miller School of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA
    J Biomed Biotechnol 2011:806506. 2011
    ..This paper tends to make a state-of-the-art review based on the available literature regarding the use of bortezomib as a single agent or in combination with chemotherapy in patients with lung cancer...
  5. doi request reprint Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor
    Edgardo S Santos
    Section of Thoracic Oncology, Sylvester Comprehensive Cancer Center, University of Miami Leonard M Miller School of Medicine, 1475 NW 12th Ave, D8 4, Miami, FL 33136, USA
    Invest New Drugs 30:1261-9. 2012
    ..The preliminary clinical efficacy of BIBF 1120 is discussed in the context of the most relevant clinical data in several malignancies including non-small cell lung cancer...
  6. doi request reprint How is gene-expression profiling going to challenge the future management of lung cancer?
    Edgardo S Santos
    Hematology Oncology Fellowship Program, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, 1475 NW 12th Avenue, Miami, FL 33136, USA
    Future Oncol 5:827-35. 2009
    ..We review the current advances in gene-expression profiling and its potential role as a diagnostic and prognostic/predictive biomarker, and how this may translate into a 'personalized medicine' for lung cancer...
  7. doi request reprint Gene expression profiling and non-small-cell lung cancer: where are we now?
    Edgardo S Santos
    University of Miami Leonard M Miller School of Medicine Sylvester Comprehensive Cancer Center, FL, USA
    Clin Lung Cancer 10:168-73. 2009
    ..Herein, we review the role of gene expression profiling in lung cancer as a diagnostic tool, predictive and prognostic biomarker, and its potential use for a "personalized" medicine in the years to come...
  8. doi request reprint Controversies in the management of stage IIIA non-small-cell lung cancer
    Edgardo S Santos
    Hematology Oncology Fellowship Program University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, 1475 NW 12th Avenue, Suite 3510, Miami, FL 33136, USA
    Expert Rev Anticancer Ther 8:1913-29. 2008
    ..We will present the current data on these debatable issues and how to implement this new knowledge into clinical practice...
  9. ncbi request reprint New targets for non-small-cell lung cancer therapy
    Manrique Alvarez
    University of Miami Miller s School Of Medicine, The William Harrington Latin American Training Program WHLTP, Division of Hematology Medical Oncology, Sylvester Comprehensive Cancer Center, 1475 NW 12 Avenue, Miami, FL 33136, USA
    Expert Rev Anticancer Ther 7:1423-37. 2007
    ..Herein, we review the most relevant clinical data using these novel targeted agents either alone or in combination with chemotherapy in non-small-cell lung cancer...
  10. doi request reprint Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC
    Michel Velez
    Department of Medicine, University of Miami Miller School of Medicine at FAU, Atlantis, FL, USA
    Expert Rev Anticancer Ther 10:549-57. 2010
    ....
  11. doi request reprint Development of targeted therapy for squamous cell carcinomas of the head and neck
    Alberto Burgos-Tiburcio
    Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA
    Expert Rev Anticancer Ther 11:373-86. 2011
    ....
  12. doi request reprint EGF receptor in lung cancer: a successful story of targeted therapy
    Gelenis Domingo
    Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, 1475 NW 12th Avenue, D8 4, Miami, FL 33136, USA
    Expert Rev Anticancer Ther 10:1577-87. 2010
    ..Our article displays the most recently developed data related to this biomarker and what have we learned based on the analyses of clinical trials that have studied different agents in the clinical arena...
  13. doi request reprint A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC)
    Luis E Raez
    Thoracic Oncology Program, Memorial Cancer Institute, Memorial Health Care System, 801 N Flamingo Road, Suite 11, Pembroke Pines, FL, 33028, USA
    Cancer Chemother Pharmacol 72:1103-10. 2013
    ..This phase II study aimed to determine the safety and efficacy of this doublet with bevacizumab as first-line treatment for stage IIIB/IV NSCLC...
  14. doi request reprint Oxaliplatin in first-line therapy for advanced non-small-cell lung cancer
    Luis E Raez
    University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Clin Lung Cancer 11:18-24. 2010
    ..However, well-conducted randomized phase III trials will be needed to clarify which particular groups of patients with NSCLC may benefit from oxaliplatin-based therapy...
  15. doi request reprint Second-line therapy for non-small-cell lung cancer
    Belisario A Arango
    Division of Hematology and Oncology, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA
    Clin Lung Cancer 10:91-8. 2009
    ..In this review, we discuss second-line treatments for patients who have NSCLC, including targeted agents and their development in this specific setting as part of our armamentarium in lung cancer...
  16. ncbi request reprint Induction chemotherapy in the management of squamous cell carcinoma of the head and neck
    Eloy Roman
    University of Miami, School of Medicine, Division of Hematology Medical Oncology, Sylvester Comprehensive Cancer Center, 1475 NW 12 Avenue, Miami, FL 33136, USA
    Expert Rev Anticancer Ther 6:1205-15. 2006
    ..This article reviews developing trends using induction chemotherapy followed by chemoradiation in patients with head and neck squamous cell carcinoma...
  17. doi request reprint Active immunotherapy for non-small-cell lung cancer: moving toward a reality
    Cesar A Perez
    University of Miami Miller School of Medicine Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA
    Expert Rev Anticancer Ther 11:1599-605. 2011
    ....
  18. ncbi request reprint Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC)
    Luis E Raez
    Division of Hematology Oncology, University of Miami Miller School of Medicine, 1475 NW 12 Avenue, Suite 3510, Miami, FL 33136, USA
    Lung Cancer 53:347-53. 2006
    ..A phase II study was conducted to evaluate the efficacy and safety of oxaliplatin combined with docetaxel for NSCLC...
  19. ncbi request reprint DNA methylation: its role in lung carcinogenesis and therapeutic implications
    Edgardo S Santos
    Division of Hematology Oncology, Tulane University Health Sciences Center, 1430 Tulane Avenue, SL 78, New Orleans, LA 70112, USA
    Expert Rev Anticancer Ther 5:667-79. 2005
    ..In this review, the authors will discuss methylation in lung carcinogenesis and its possible clinical implications...
  20. doi request reprint Concurrent chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy (sequential approach) in the management of head and neck cancer
    Jesus C Fabregas
    Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA
    Expert Rev Anticancer Ther 13:1065-72. 2013
    ..Different factors including toxicity profile, adherence and patient characteristics play a major role in choosing the most appropriate treatment regimen. ..
  21. ncbi request reprint Clinical trials targeting lung cancer with active immunotherapy: the scope of vaccines
    Luis E Raez
    Division of Hematology Oncology, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, 1475 NW 12 Avenue, Miami, FL 33136, USA
    Expert Rev Anticancer Ther 5:635-44. 2005
    ..In this review, the rationale and design for induction of immunity to non-small cell lung cancer and clinical trials of the most important lung cancer vaccines in development are discussed...
  22. ncbi request reprint Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature
    Edgardo S Santos
    Division of Hematology Oncology, Tulane University Health Sciences Center, New Orleans, LA 70112, USA
    Liver Int 26:625-9. 2006
    ..Prospective randomized studies in AIH are needed to validate this observation...
  23. pmc Primary Mediastinal Large B-Cell Lymphoma during Pregnancy
    Cesar A Perez
    Division of Hematology Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, 1475 NW 12th Avenue, Miami, FL 33136, USA
    Case Report Hematol 2012:197347. 2012
    ..PMLBCL, although an uncommon subgroup of DLBCL, may present during pregnancy and R-CHOP should be considered as one suitable option in this complex scenario...
  24. doi request reprint Biomarkers, prediction, and prognosis in non-small-cell lung cancer: a platform for personalized treatment
    Akshay Sudhindra
    Sylvester Comprehensive Cancer Center University of Miami Leonard M Miller School of Medicine, Miami, FL 33136, USA
    Clin Lung Cancer 12:360-8. 2011
    ..We hope that the clinical use of biomarkers will help us to deliver personalized medicine to our lung cancer patients by improving their quality of response which may translate into further survival advantage...
  25. pmc Efficacy of sorafenib, a multi-tyrosine kinase inhibitor, in an adenoid cystic carcinoma metastatic to the lung: case report and review of literature
    Daniel J Dammrich
    University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, USA
    J Med Case Reports 5:483. 2011
    ..abstract:..
  26. pmc Systemic lupus erythematosus presenting as thrombotic thrombocytopenia purpura: how close is close enough?
    Cesar A Perez
    Division of Hematology Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, 1475 NW 12th Avenue, D8 4 Suite 3510, Miami, FL 33136, USA
    Case Report Med 2011:267508. 2011
    ..An underlying diagnosis of SLE should be considered in all patients presenting TTP and the study of this association may provide a better understanding of their immune-mediated pathophysiology...